Steve Ferguson appointed new CEO of Medix Biochemica

Press release 15.10.2019

  • Steve Ferguson has been appointed CEO of Medix Biochemica starting 1 January 2020
  • Ismo Råman to assist in the CEO transition and continue as a senior advisor of Medix Biochemica
  • Medix Biochemica has significant international growth plans in the in vitro diagnostics (“IVD”) industry

The Board of Directors of Medix Biochemica has appointed Steve Ferguson as the new CEO of the company starting 1 January 2020. The current CEO of Medix Biochemica, Ismo Råman, will continue in his role until 31 December 2019 and will thereafter support the CEO transition and in other activities as a senior advisor of Medix Biochemica.

Steve Ferguson joins Medix Biochemica from Thermo Fisher Scientific’s ImmunoDiagnostics Division, where he has been Vice President of European Commercial Operations since 2015. Before joining Thermo Fisher Scientific in 2012, Steve Ferguson held various management positions in Lundbeck Ltd.

”Medix Biochemica has a clear strategy to become the #1 choice for IVD test manufacturers by focusing on commercial excellence and expansion of high-quality product offering. The Board of Directors is convinced that Steve Ferguson has the right set of values, skills and experience to lead Medix Biochemica through its next growth stage. We would also like to thank Ismo Råman for his dedication and outstanding contribution to Medix Biochemica’s growth story in the past 20 years”, says Ann-Christine Sundell, Chairman of the Board of Medix Biochemica.

”I look forward to joining Medix Biochemica and leading the company towards its ambitious vision. The company’s excellent reputation for high-quality products, skilled employees and strong long-term ownership base provide a great foundation for the work ahead.”, says Steve Ferguson, the incoming CEO of Medix Biochemica.

Medix Biochemica is a leading manufacturer of bioreagents for the global IVD industry. In addition, it offers diagnostic tests specifically designed for the women’s health sector. Medix Biochemica was founded in 1985 and it currently employs c. 120 people at its facilities in Finland, USA and China. Medix Biochemica sales in 2018 amounted to EUR 23 million.

 More information:

Ann-Christine Sundell
Mobile: +358 40 536 7703
Email: ac.sundell@parnet.fi

Ismo Råman
Mobile: +358 40 702 4757
Email: ismo.raman@medixbiochemica.com